{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:40:20Z","timestamp":1771328420616,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11910-017-0711-8","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T07:08:15Z","timestamp":1488784095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics"],"prefix":"10.1007","volume":"17","author":[{"given":"Tiago A.","family":"Mestre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"711_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"H. s. D. C. R. Group","year":"1993","unstructured":"H. s. D. C. R. Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"711_CR2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391.","journal-title":"Mov Disord"},{"key":"711_CR3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"\u2022 Rawlins MD et al. The prevalence of Huntington\u2019s disease. Neuroepidemiology. 2016;46:144\u201353. This paper is the most recent review on epidemiology of Huntington\u2019s disease.","journal-title":"Neuroepidemiology"},{"key":"711_CR4","volume-title":"GeneReviews","author":"SC Warby","year":"1993","unstructured":"Warby SC, Graham RK, Hayden MR. Huntington disease. In: Pagon RA et al., editors. GeneReviews. Seattle: University of Washington; 1993."},{"key":"711_CR5","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. 2009;3CD006456.","DOI":"10.1002\/14651858.CD006456.pub2"},{"key":"711_CR6","unstructured":"Merchant K. Target Validation; Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. Forum on Neuroscience and Nervous System Disorders; Board on Health Sciences Policy; Institute of Medicine, 2014."},{"key":"711_CR7","doi-asserted-by":"crossref","unstructured":"Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology. 2016.","DOI":"10.1016\/j.neuropharm.2016.03.021"},{"key":"711_CR8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.drudis.2011.09.007","volume":"16","author":"I Gashaw","year":"2011","unstructured":"Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today. 2011;16:1037\u201343.","journal-title":"Drug Discov Today"},{"key":"711_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","volume":"33","author":"P Dayalu","year":"2015","unstructured":"Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurol Clin. 2015;33:101\u201314.","journal-title":"Neurol Clin"},{"key":"711_CR10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0896-6273(95)90106-X","volume":"15","author":"N Aronin","year":"1995","unstructured":"Aronin N et al. CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. Neuron. 1995;15:1193\u2013201.","journal-title":"Neuron"},{"key":"711_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ et al. Potential endpoints for clinical trials in pre-manifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11:42\u201353.","journal-title":"Lancet Neurol"},{"key":"711_CR12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P","volume":"15","author":"EH Aylward","year":"2000","unstructured":"Aylward EH et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord. 2000;15:552\u201360.","journal-title":"Mov Disord"},{"key":"711_CR13","doi-asserted-by":"crossref","unstructured":"\u2022Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium. Identification of genetic factors that modify clinical onset of Huntington's disease. Cell. 2015;162:516\u201326. This paper identifies additional genetic factors beyond CAG repeat length in the huntingtin gene that can determine clinical onset of Huntington's disease with implications in clinical research identifying nonmanifesting carriers that are at greater risk of phenoconversion.","DOI":"10.1016\/j.cell.2015.07.003"},{"key":"711_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003930","volume":"9","author":"RM Pinto","year":"2013","unstructured":"Pinto RM et al. Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington's disease mice: genome-wide and candidate approaches. PLoS Genet. 2013;9, e1003930.","journal-title":"PLoS Genet"},{"key":"711_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, I. H. s. D. C. Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65:267\u201377.","journal-title":"Clin Genet"},{"key":"711_CR16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"JM Lee","year":"2012","unstructured":"Lee JM et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78:690\u20135.","journal-title":"Neurology"},{"key":"711_CR17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/jmg.31.11.872","volume":"31","author":"K Kieburtz","year":"1994","unstructured":"Kieburtz K et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet. 1994;31:872\u20134.","journal-title":"J Med Genet"},{"key":"711_CR18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.46.2.527","volume":"46","author":"J Brandt","year":"1996","unstructured":"Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology. 1996;46:527\u201331.","journal-title":"Neurology"},{"key":"711_CR19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/mds.21988","volume":"23","author":"B Ravina","year":"2008","unstructured":"Ravina B et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord. 2008;23:1223\u20137.","journal-title":"Mov Disord"},{"key":"711_CR20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mds.24024","volume":"27","author":"A Rosenblatt","year":"2012","unstructured":"Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA. Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord. 2012;27:272\u20136.","journal-title":"Mov Disord"},{"key":"711_CR21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90:905\u201381.","journal-title":"Physiol Rev"},{"key":"711_CR22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.26006","volume":"29","author":"L Menalled","year":"2014","unstructured":"Menalled L, Brunner D. Animal models of Huntington's disease for translation to the clinic: best practices. Mov Disord. 2014;29:1375\u201390.","journal-title":"Mov Disord"},{"key":"711_CR23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijdevneu.2005.10.001","volume":"24","author":"SJ Jeong","year":"2006","unstructured":"Jeong SJ, Kim M, Chang KA, Kim HS, Park CH, Suh YH. Huntingtin is localized in the nucleus during preimplanatation embryo development in mice. Int J Dev Neurosci. 2006;24:81\u20135.","journal-title":"Int J Dev Neurosci"},{"key":"711_CR24","first-page":"4","volume":"9","author":"WL Yang","year":"2016","unstructured":"Yang WL, Tu ZC, Sun Q, Li XJ. CRISPR\/Cas9: implications for modeling and therapy of neurodegenerative diseases. Front Mol Neurosci Rev. 2016;9:4.","journal-title":"Front Mol Neurosci Rev"},{"key":"711_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86:29\u201336.","journal-title":"Clin Genet"},{"key":"711_CR26","unstructured":"Macdonald D, et al. Pharmacodynamic biomarkers for HTT-lowering therapies: a white paper. CHDI Management\/CHDI Foundation, 2015."},{"key":"711_CR27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fnmol.2014.00050","volume":"7","author":"M Bourdenx","year":"2014","unstructured":"Bourdenx M, Dutheil N, Bezard E, Dehay B. Systemic gene delivery to the central nervous system using Adeno-associated virus. Front Mol Neurosci. 2014;7:50.","journal-title":"Front Mol Neurosci"},{"key":"711_CR28","unstructured":"\u2022\u2022 Tabrizi S. HTT Rx CS1 Trial. Available at: http:\/\/chdifoundation.org\/2016-conference\/Accesse August 4, 2016. This oral presentation provides core information on the development and conduction of the first in-human study on huntingtin lowering therapies conducted in Huntington's disease, using a nonallele-specific antisense oligonucleotide ."},{"key":"711_CR29","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1523\/JNEUROSCI.22-11-04478.2002","volume":"22","author":"V Mittoux","year":"2002","unstructured":"Mittoux V et al. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci. 2002;22:4478\u201386.","journal-title":"J Neurosci"},{"key":"711_CR30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","volume":"20","author":"N Wang","year":"2014","unstructured":"Wang N et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med. 2014;20:536\u201341.","journal-title":"Nat Med"},{"key":"711_CR31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031\u201344.","journal-title":"Neuron"},{"key":"711_CR32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009;17:1053\u201363.","journal-title":"Mol Ther"},{"key":"711_CR33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi MS et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol. 2009;217:312\u20139.","journal-title":"Exp Neurol"},{"key":"711_CR34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol. 2009;19:774\u20138.","journal-title":"Curr Biol"},{"key":"711_CR35","unstructured":"Center for Drug Evaluation and Research, U.S. Department of Health and Human Services Food and Drug Administration for Industry and FDA Staff Qualification Process for Drug Development Tools, 2014."},{"key":"711_CR36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"\u2022 Wild EJ et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest. 2015;125:1979\u201386. This paper provides the first method to sucessfully quantify huntingtin in the cerebral spinal fluid in patients with Huntington's disease.","journal-title":"J Clin Invest"},{"key":"711_CR37","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington's disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1171\u201382. This review provides a comprehensive overview of current state of PET imaging in Huntington's disease.","DOI":"10.1007\/s00259-016-3324-6"},{"key":"711_CR38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JHD-140129","volume":"3","author":"S Miller","year":"2014","unstructured":"Miller S, Hill Della Puppa G, Reidling J, Marcora E, Thompson LM, Treanor J. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6\/2 and BACHD mouse models of Huntington's disease. J Huntingtons Dis. 2014;3:333\u201341.","journal-title":"J Huntingtons Dis"},{"key":"711_CR39","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.neurobiolaging.2014.06.010","volume":"35","author":"M Ooms","year":"2014","unstructured":"Ooms M et al. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6\/2 Huntington mice. Neurobiol Aging. 2014;35:2858\u201369.","journal-title":"Neurobiol Aging"},{"key":"711_CR40","first-page":"S63","volume":"28","author":"D Jennings","year":"2013","unstructured":"Jennings D et al. Examining expression of phosphodiesterase 10A (PDE10A) in Huntington's disease using 18F-MNI-659 PET. Mov Disord. 2013;28:S63.","journal-title":"Mov Disord"},{"key":"711_CR41","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1002\/mds.25650","volume":"29","author":"C Fitzer-Attas","year":"2014","unstructured":"Fitzer-Attas C et al. Imaging of phosphodiesterase 10A (PDE10A) enzyme and D-2 receptor levels in the living brain of Huntington's disease gene expansion carriers and healthy controls. Mov Disord. 2014;29:S207\u20138.","journal-title":"Mov Disord"},{"key":"711_CR42","first-page":"S539","volume":"30","author":"C Fitzer-Attas","year":"2015","unstructured":"\u2022 Fitzer-Attas C et al. Dopamine D2 receptor and phosphodiesterase 10A loss in Huntingtons disease measured with high-resolution PET and partial volume effect correction. Mov Disord. 2015;30:S539. This paper reports on development of phosphodiesterase 10A as target for PET imaging in Huntington's disease.","journal-title":"Mov Disord"},{"key":"711_CR43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","volume":"86","author":"DS Russell","year":"2016","unstructured":"\u2022 Russell DS et al. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Neurology. 2016;86:748\u201354. This paper reports the first longitudinal study on phosphodiesterase 10A as target for PET imaging in Huntington's disease.","journal-title":"Neurology"},{"key":"711_CR44","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/brain\/awv214","volume":"138","author":"F Niccolini","year":"2015","unstructured":"Niccolini F et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain. 2015;138:3016\u201329.","journal-title":"Brain"},{"key":"711_CR45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.nicl.2013.03.001","volume":"2","author":"EM Dumas","year":"2013","unstructured":"Dumas EM et al. Reduced functional brain connectivity prior to and after disease onset in Huntington's disease. Neuroimage Clin. 2013;2:377\u201384.","journal-title":"Neuroimage Clin"},{"key":"711_CR46","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ebiom.2015.08.002","volume":"2","author":"S Kloppel","year":"2015","unstructured":"Kloppel S et al. Compensation in preclinical Huntington's disease: evidence from the track-on HD Study. EBioMed. 2015;2:1420\u20139.","journal-title":"EBioMed"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-017-0711-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T11:03:25Z","timestamp":1601723005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-017-0711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s11910-017-0711-8","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"article-number":"18"}}